Related by context. All words. (Click for frequent words.) 71 F#del mutation 59 chronic HCV infection 59 ApoE gene 59 autoantibody positive 59 FTO allele 58 CFTR gene 58 Acute myeloid leukemia 58 EGFR gene 58 null responder HCV 58 treatment naive genotype 58 ApoE4 gene 58 chronic HBV 57 T1DM 57 APOE e4 gene 57 relapsed ALL 57 recurrent malignant glioma 57 pediatric acute lymphoblastic 57 FTO variant 57 Myelodysplastic syndromes MDS 57 leukemia AML 57 C#Y 57 late onset Pompe 56 cutaneous T 56 forodesine 56 refractory chronic lymphocytic 56 aged ≥ 56 symptomatic BPH 56 Chronic Idiopathic Constipation 56 tumor specific antigen 56 familial hypercholesterolemia 56 Wwox 56 acute myeloid 56 eosinophilic asthma 56 acute myelogenous leukemia AML 55 number variations CNVs 55 hepatitis C genotype 55 autosomal recessive disease 55 HBeAg negative 55 phase IIb study 55 Phase III randomized controlled 55 relapsed refractory AML 55 NOMID 55 APOE e4 55 HER2 gene 55 Waldenstrom macroglobulinemia 55 Phase 2a trial 55 LRAT 55 HeFH 55 pediatric glioma 55 Phase Ib clinical 55 G#D 55 HIV uninfected 55 Chronic lymphocytic leukemia 55 immunocompetent 55 alvespimycin 55 number variants CNVs 55 OvaRex ® MAb 55 cystic fibrosis CF 55 UGT#A# * 55 faulty BRCA2 gene 55 BCG vaccinated 55 nonsense mutation 55 hepatitis C HCV 55 HIV HCV coinfected 55 relapsed MM 55 chronic myeloid 54 APOE4 54 CDH1 54 glucocorticoid induced osteoporosis 54 recurrent glioblastoma multiforme 54 DEB# 54 SMN2 gene 54 HCV infected 54 ApoE4 54 chronic HCV 54 NPM1 mutations 54 ApoE4 allele 54 sporadic ALS 54 phase IIb clinical 54 retrospective cohort 54 multicenter Phase II 54 papillary renal cell carcinoma 54 genetic variants associated 54 RPE# 54 Tanespimycin 54 dose cohort 54 hypereosinophilic syndrome 54 Chronic myeloid leukemia 54 RPE# gene 54 Wisconsin Sleep Cohort 54 hyperphenylalaninemia HPA due 54 elevated triglyceride levels 54 CTAP# Capsules 54 CIMZIA TM certolizumab pegol 54 metastatic bladder 54 Evoltra ® 54 heavily pretreated 54 unresectable recurrent 54 HBeAg positive 54 treatment naïve genotype 54 diabetic neuropathic pain 54 STK# gene 54 systemic lupus erythematosus SLE 54 mutated K ras 54 prostate cancer CaP 54 recurrent metastatic 54 clinical pharmacology studies 54 OPT CHF 54 R#/MEM # 54 INS# [001] 53 quadrivalent HPV vaccine 53 antiretroviral naive 53 thorough QT 53 lymphoid malignancies 53 number NCT# ClinicalTrials.gov 53 Li Fraumeni 53 proliferative retinopathy 53 denufosol 53 Alzheimer disease cognitive impairment 53 discontinued Viread 53 blinded randomized placebo controlled 53 INSPIRE Trial Phase III 53 Kit CD# positive 53 Hp2 2 53 Fragile X gene 53 hypoparathyroidism 53 basal cell nevus syndrome 53 GBM tumors 53 RSD# oral 53 Duchenne Muscular Dystrophy DMD 53 GARDASIL ® 53 Acute Myeloid Leukaemia AML 53 MTHFR 53 enteroviral infection 53 placebo controlled Phase 53 MYH9 gene 53 diffuse gastric 53 C1 INH deficiency 53 Severe Primary IGFD 53 ABSSSI 53 heterozygous FH 53 Phase IIa trials 53 CFTR corrector 53 FOLOTYN ® 53 operable breast cancer 53 BRCA2 gene 53 mildly symptomatic 53 trastuzumab Herceptin ® 53 PNP inhibitor 53 rALLy 53 leukemia ALL 53 5 HTT gene 53 PROSTVAC VF 53 nondemented 53 virus HCV infection 53 APOE gene 53 Relapsing remitting MS 53 Phase IIa trial 53 HCV SPRINT 53 vWD 53 lupus nephritis 53 Omacetaxine 53 onset idiopathic hypogonadism 53 Her2 gene 53 BMPR2 53 HCV genotype 1 53 TGFBR1 * 6A 53 ELACYT 53 refractory CLL 53 Glioblastoma multiforme GBM 53 basal cell carcinoma BCC 53 Myelodysplastic syndromes 53 COU AA 53 APOE4 gene 53 phase IIa clinical 53 Twinrix 53 AEG# 53 proband 53 KRAS mutations occur 53 neovascular form 53 T#I mutation 53 smoldering multiple myeloma 53 TTR amyloidosis 53 CC genotype 53 aggressive systemic mastocytosis 53 E4 variant 53 nonsense mutations 53 Duchenne muscular dystrophy DMD 53 nonsmall cell lung cancer 53 GH deficiency 53 stage IIIB IV 53 LHON 53 dosing cohort 53 decompensated liver disease 53 recurrent glioma 53 Framingham Offspring Study 52 abnormal cytology 52 postmenopausal osteoporotic women 52 LTBI 52 GPC5 52 visilizumab 52 relapsing remitting MS RRMS 52 grade cervical dysplasia 52 PANVAC VF 52 Phase IIa clinical 52 subcutaneous PRO 52 MGd 52 novel VDA molecule 52 squamous cell lung cancer 52 Leber congenital amaurosis LCA 52 leukaemias 52 Familial Adenomatous Polyposis FAP 52 primary generalized tonic 52 medulloblastomas 52 acute leukemias 52 HLA B# 52 phase IIb trial 52 cognitively normal 52 CMV infection 52 AGHD 52 GBA mutations 52 acute lymphoid leukemia 52 HIV coinfected 52 evaluable subjects 52 Callisto initiated 52 refractory chronic myeloid 52 nitazoxanide 52 PROSTVAC ® 52 relapsed refractory multiple myeloma 52 FTO gene variant 52 KIF6 gene 52 initiate Phase 1b 52 Phase IIIb clinical 52 variant allele 52 BRCA2 gene mutation 52 previously untreated follicular 52 multiple ascending dose 52 Sapacitabine 52 oral ridaforolimus 52 Velcade bortezomib 52 smoldering myeloma 52 refractory acute myeloid 52 systemic ALCL 52 R roscovitine 52 miglustat 52 Gleevec resistant 52 ragweed allergic 52 heterozygous familial hypercholesterolemia 52 Cloretazine 52 rindopepimut 52 AAT deficiency 52 CEQ# 52 grade cervical intraepithelial 52 castrate resistant prostate cancer 52 LHRH receptor positive 52 dose escalation Phase 52 gastrointestinal stromal tumors 52 CCR5 tropic HIV 52 underwent liver transplantation 52 osteoporotic vertebral compression fractures 52 SNT-MC#/idebenone 52 PDGFRA 52 HCV RESPOND 2 52 AIR CF1 52 VUR 52 metastatic hormone refractory 52 BRIM2 52 AVN# Phase 52 LC#m# vaccine 52 Phase #/#a trial 52 Phase 1b clinical 52 HIV seronegative 52 prospective observational cohort 52 chlamydial infection 52 histologic subtype 52 Phase 2a clinical 52 huN# DM1 52 C#Y mutation 52 Arranon 52 Heterozygous Familial Hypercholesterolemia 52 prelicensure 52 lacunar 52 Hodgkin lymphoma HL 52 KRAS wild 52 hemodialysis patients 52 Clinicaltrials.gov 52 Phase #b/#a clinical 52 pneumococcal pneumonia 52 Swedish Mammography Cohort 52 CCL#L# 52 osteosarcomas 52 hereditary deficiency 52 de novo AML 52 Phase 2a clinical trials 52 pneumococci 52 Posiphen 52 COMT gene 52 recurrent NSCLC 52 SOD1 gene 52 cervical vulvar 52 orally administered synthetic retinoid 51 XL# SAR# 51 Enzastaurin 51 immunocompetent adults 51 liver transplantations 51 lumiliximab 51 JAK2 inhibitor 51 idiopathic thrombocytopenic purpura 51 defective CFTR 51 Phase 1b trial 51 psoriatic arthritis PsA 51 BRIM3 51 severely immunocompromised 51 diagnosed Ph + 51 IDH2 51 Human Papillomavirus Quadrivalent Types 51 cell lymphoma CTCL 51 dose escalation phase 51 thetreatment 51 sargramostim 51 Prostate Lung Colorectal 51 atypical hemolytic uremic syndrome 51 Hepsera adefovir dipivoxil 51 cognitively intact 51 confirmatory clinical 51 naïve HCV 51 atherothrombosis 51 haptoglobin 51 HCV genotypes 51 human leukocyte antigen HLA 51 BRIP1 51 lymphoma CTCL 51 pertussis Tdap vaccine 51 F#del 51 metastatic renal cell 51 GV# [001] 51 autosomal 51 Bronchiectasis 51 attention-deficit/hyperactivity disorder ADHD 51 familial ALS 51 brivanib 51 Blinatumomab 51 unresectable stage 51 ascending doses 51 leukemia CLL 51 HFE gene 51 Bezielle 51 nucleotide analog 51 ChronVac C R 51 progressive PsA 51 alpha1 antitrypsin AAT deficiency 51 Acute Myeloid Leukemia AML 51 BRAF mutation 51 decitabine 51 longitudinal cohort study 51 Phase Ib 51 chronic idiopathic constipation 51 HER2 positive metastatic breast 51 oral JAK#/JAK# inhibitor 51 BRCA2 mutation carriers 51 Phase Ib IIa 51 NYHA Class II 51 homozygous FH 51 hematopoietic malignancies 51 pharyngeal cancer 51 HQK 51 protease inhibitor PI 51 dirucotide MBP# 51 infantile onset 51 synthetic retinoid 51 orally administered inhibitor 51 Phase IIb trial 51 EOquin 51 recurrent glioblastoma multiforme GBM 51 seropositive patients 51 exomes 51 virus HCV protease inhibitor 51 COPD exacerbation 51 Phase 1a clinical 51 ADPKD 51 NF1 51 relapsed AML 51 overt nephropathy 51 chronic eosinophilic leukemia 51 GATTEX ® 51 progranulin mutations 51 Lung transplantation 51 dosing cohorts 51 crizotinib PF # 51 single ascending dose 51 Vaccine Recombinant 51 Phase IIa clinical trials 51 muscular dystrophy cystic fibrosis 51 Framingham Offspring 51 REVIVE Diabetes 51 journal Ophthalmology 51 Azedra 51 progressive neurodegenerative disorder 51 BRCA mutation 51 chronic plaque psoriasis 51 dyskeratosis congenita 51 NPHP 51 ruxolitinib 51 Phase #b/#a 51 histologically confirmed 51 debilitating autoimmune 51 genotypic resistance 51 antibody MAb 51 Sprycel dasatinib 51 PPSV# 51 nonalcoholic steatohepatitis NASH 51 HbF 51 hereditary predisposition 51 Poly ICLC 51 galiximab 51 NNRTI resistance 51 chronic ITP 51 multiple myeloma MM 51 CARDIA 51 dose escalation study 51 MAGE A3 ASCI 51 CATIE AD 51 SGS# 51 trivalent inactivated influenza 51 ANCHOR trial 51 progranulin gene 51 oral squamous cell 51 partial onset seizures 51 external genital lesions 51 Arch Intern Med 51 BRCA mutations 51 castration resistant prostate cancer 51 relapsed mantle 51 weekly intravenous infusions 51 peritumoral brain edema 51 myeloproliferative disorders 51 #q# deletion 51 GCase 51 CCR5 delta# 51 AML MDS 51 myelofibrosis 51 non CF bronchiectasis 51 tramiprosate Alzhemed TM 51 familial pancreatic cancer 51 toenail onychomycosis 51 BR.# 51 Aviptadil 51 Philadelphia Chromosome Positive 51 pelvic malignancies 51 placebo controlled Phase III 51 TACI mutations 51 confirmatory Phase IIIb 51 Solorel 51 KIBRA 51 lomitapide 51 SHANK3 gene 51 chronic hepatitis C. 51 mutated genes 51 OncoVEX GM CSF 51 untreated AML 51 INTERHEART study 51 AVODART 51 RTP #i 51 CIMZIA ™ 51 engineered urethras 51 defective gene 51 uncomplicated influenza 50 narcolepsy cataplexy 50 NXL# 50 mtDNA mutations 50 APOE allele 50 placebo controlled clinical 50 dacarbazine DTIC 50 simplex virus 50 Epstein Barr virus EBV 50 SHANK3 50 nucleoside naive 50 trastuzumab emtansine T DM1 50 HCV infection 50 Temsirolimus 50 Plicera 50 PD LID 50 Diamyd r 50 PRIMO CABG 50 PLUS LIFELONG FITNESS 50 commercialize deforolimus 50 mutated gene 50 abnormal lipid 50 PREZISTA r 50 severe congenital neutropenia 50 HuLuc# 50 Attention-Deficit/Hyperactivity Disorder ADHD 50 bodyguards Andarbi 50 MEK inhibitor 50 dose escalation clinical 50 acute myeloid leukemia AML 50 lintuzumab SGN 50 MCV4 50 ENVISION 50 Ophena TM 50 tuberous sclerosis TS 50 pilocytic astrocytomas 50 SNT MC# 50 myelodysplastic myeloproliferative diseases 50 DBMD 50 tumorigenicity 50 common disabling neurological 50 poor metabolizers 50 Prodarsan ® 50 SJIA 50 gastrointestinal stromal tumors GISTs 50 plaque psoriasis 50 germline mutation 50 T2DM 50 macroglobulinemia 50 H#N# monovalent vaccine 50 B CLL 50 Multicenter AIDS 50 TLR antagonists 50 BARACLUDE ® 50 Uterine cancer 50 onset seizures 50 antiretroviral naïve 50 heterozygous 50 RNAi therapeutic targeting 50 Virulizin ® 50 HBV infections 50 cytarabine daunorubicin 50 underwent surgical resection 50 pancreatic insufficiency 50 LUX Lung 50 SOD2 gene 50 cardioembolic stroke 50 transthyretin amyloidosis 50 placebo controlled clinical trials 50 cancerous prostates removed 50 relapsing multiple sclerosis 50 virus HBV 50 HPV subtypes 50 ductal adenocarcinoma 50 seroconverted 50 ataluren 50 mcg albinterferon alfa 2b 50 irinotecan chemotherapy 50 homozygous familial hypercholesterolemia 50 Cimzia ® certolizumab pegol 50 Curaxin CBLC# 50 ostarine 50 refractory metastatic 50 Bipolar disorder affects 50 atopic asthma 50 double blinded placebo 50 MLL2 50 pheochromocytoma 50 orally bioavailable 50 testicular germ cell 50 MYCN amplification 50 amoxicillin clavulanate 50 reduce serum phosphate 50 kidney urologic 50 medulloblastoma tumors 50 STEP BD 50 riociguat 50 chronic granulomatous disease 50 CIMZIA TM 50 JAK inhibitors 50 brivaracetam 50 oral ghrelin agonist 50 FLT3 mutations 50 chronic HBV infection 50 CAMMS# 50 secretory diarrhea 50 syngeneic 50 evaluating mipomersen 50 myelodysplastic syndrome MDS 50 autosomal recessive disorder 50 Lymphocytic 50 Tesmilifene 50 genetic variant 50 RSV infects 50 AML acute myeloid 50 onset diabetes mellitus 50 degenerative neurological diseases 50 hepatorenal syndrome 50 LQTS 50 metastatic castrate resistant 50 COPEGUS ribavirin 50 Cimzia TM 50 HGS ETR1 50 number variation CNV 50 hepatocellular cancer 50 receiving antiretroviral therapy 50 EGFR mutation 50 Human papillomavirus HPV 50 autosomal recessive 50 metastatic renal 50 tarenflurbil 50 refractory anaplastic astrocytoma 50 Human Mutation 50 PRTX 50 High Dose quadruples 50 Diabetic Macular Edema 50 tanespimycin 50 glucokinase activators 50 BRCA2 carriers 50 gene APOE4 50 systemic lupus erythematosus 50 Chronic myeloid leukemia CML 50 Phenylketonuria PKU 50 elotuzumab 50 Sjögren syndrome 50 BRCA mutation carriers 50 hematologic disorders 50 HCV replicon 50 Clinical Antipsychotic Trials 50 RhuDex ™ 50 K ras mutations 50 diabetic retinopathy DR 50 PSMA ADC 50 Phase 2b trial 50 HGPS 50 RSV infection 50 meningococcal conjugate vaccine 50 subependymal giant cell 50 ENESTnd 50 Annamycin 50 immunological diseases 50 mRCC 50 prospectively defined 50 Phase IIb clinical trials 50 multicenter Phase III 50 HER2 expression 50 1 diabetes T1D 50 familial adenomatous polyposis 50 candidemia 50 metastatic neuroendocrine tumors 50 rALLy clinical trial 50 gastrin analogue TT 50 Naive Patients 50 transgenic mouse models 50 highly immunogenic 50 Xyfid TM 50 Myotonic dystrophy 50 Pneumococcal vaccines 50 2 diabetes T2D 50 alemtuzumab treated 50 Pulmonary arterial hypertension 50 IgA deficiency 50 Diamyd ® 50 AIR2 Trial 50 Ph + ALL 50 molecular abnormalities 50 Ph + acute lymphoblastic 50 hepatitis C virus HCV 50 cervical intraepithelial neoplasia 50 TOMM# 50 Novartis MenB vaccine 50 precancerous cervical lesions 50 non nucleoside HCV 50 HCV genotype 50 Sudhir Agrawal D.Phil 50 viral kinetics 50 PSN# [002] 50 pharmacodynamic profile 50 CYT# potent vascular disrupting 50 phase III ACCLAIM 50 metastatic malignant 50 type 1diabetes 50 GRN# 50 chronic myeloid leukemia CML 50 upper limb spasticity 50 CDKN2A 50 Phase IIb trials 50 RhuDex R 50 Myelodysplasia 50 careHPV 50 histologically proven 50 unstable angina UA 50 follicular lymphoma FL 50 non metastatic osteosarcoma 50 CCR5 mAb 50 Phase 2b study 50 Vascugel ™ 50 CARDIA study 50 TELINTRA 50 alpha antagonist 50 herpes zoster shingles 50 AERAS-#/Crucell Ad# 50 breast carcinoma 50 tumors GIST 50 CIN2 + 50 anal intraepithelial neoplasia 50 glioblastoma tumors 50 A3 adenosine receptor 50 gene variant 50 refractory prostate cancer 50 GAMMAGARD 50 Dacogen injection 50 Idiopathic Pulmonary Fibrosis IPF 50 NRTI resistance 50 lung adenocarcinoma 50 cell acute lymphoblastic 50 IIa trial 50 lymphocytic choriomeningitis virus LCMV 50 Pollster Populus interviewed 50 latent tuberculosis infection 50 Folfox 50 RRMS patients 50 canakinumab 50 RSV infections 50 HGS# 50 HER2 positive cancers 50 oncogenic HPV 50 EDEMA3 50 FGFR2 50 Depressive disorders afflict 50 FLT3 50 Seliciclib 50 HF ACTION 50 Nonalcoholic fatty liver 50 relapsed MCL 50 telaprevir VX 50 asymptomatically 50 seliciclib 50 cisplatin chemotherapy 50 chronic idiopathic thrombocytopenic purpura 50 TÎ ² 4 50 conjugate pneumococcal vaccine 50 Major depressive disorder 50 von Willebrand disease 50 recurrent glioblastoma 50 G#S mutation 50 hepatitis B virus HBV 50 ATG#L# 50 schizophreniform disorder 50 fatal myelination disorder 50 Netherlands Cohort Study 50 thrombocytopenic 50 Sanofi Pasteur Fluzone 50 Squamous 50 pyridostigmine 50 venlafaxine XR 50 BRAF V# mutation 50 acute GvHD 50 CHDs 50 Chronic lymphocytic leukemia CLL 50 inherited mutations 50 journal Rheumatology 50 RSV hospitalizations 50 rheumatoid arthritis osteoarthritis ankylosing 50 genomic biomarker 50 refractory multiple myeloma 50 erlotinib Tarceva ® 50 TYGACIL 50 TCF#L# gene 50 hormone deprivation 50 radezolid 50 mCRC patients 50 telaprevir dosing 49 controlled dose escalation 49 PAOD 49 oral deforolimus 49 oral FTY# 49 ganetespib 49 colorectal tumor 49 Ets2 49 biologic DMARD 49 mg/m2 dose 49 pancreatic adenocarcinoma 49 TTR gene 49 FMR1 gene 49 metastatic malignant melanoma 49 DICER1 gene 49 autosomal dominant disorder 49 adult chronic ITP 49 olaparib 49 primary humoral immunodeficiency 49 phase IIa 49 chronic HCV genotype 49 CHAMPION PCI 49 journal Oncogene 49 Raptiva ® 49 NATRECOR R 49 acid phosphatase PAP 49 chronic immune thrombocytopenic 49 c KIT 49 AIDS Clinical Trials 49 chronic ITP patients 49 ependymoma 49 methylation markers 49 genital HPV 49 CLL SLL 49 oligodendrogliomas 49 blinded placebo controlled 49 Frank Corsaro Brundibar 49 MORAb 49 relapsed leukemia 49 immunodeficiencies 49 HoFH 49 standard chemotherapy regimen 49 patientswith 49 CERE 49 flutamide 49 CHOP chemotherapy 49 Sym# 49 low dose cytarabine 49 Aortic stenosis 49 colorectal neoplasia 49 pegylated interferon alpha 49 CDK inhibitor 49 metastatic gastric 49 octreotide implant 49 Cutaneous T 49 chemoresistant 49 chronic thromboembolic pulmonary 49 Heplisav 49 Hurler syndrome 49 immuno compromised individuals 49 BRCA1 mutation carriers 49 BLA submission 49 CCR5 receptor antagonist 49 PKCi 49 cytomegalovirus CMV 49 designated HVTN 49 cranial radiation 49 mcg doses 49 underwent radical prostatectomy 49 autosomal dominant 49 hepatitis C virus 49 ZOLINZA 49 ACE2 gene 49 Li Fraumeni syndrome 49 Vicinium TM 49 BRCA2 mutations 49 Lafora disease 49 recurrent VTE 49 Rheumatoid arthritis affects 49 pharmacokinetic PK 49 myeloproliferative neoplasms 49 ComRes telephoned 49 p# biomarker 49 G allele 49 Primary IGFD 49 lymphoid tumors 49 ThermoDox ® clinical 49 Duchenne Becker 49 Chronic Lymphocytic Leukemia CLL 49 NOX E# 49 gene variation 49 telomere lengths 49 MAGE A3 protein 49 sodium glucose cotransporter 49 nondiabetic 49 prognostic indicators 49 Populus interviewed random 49 ALN TTR 49 ritonavir boosted protease inhibitor 49 Enrique Naputi 49 metastatic HRPC 49 CALGB # [002] 49 serum PTH 49 neuroblastoma tumors 49 Ovarian PLCO Cancer 49 Alemtuzumab 49 bicifadine 49 IIa clinical 49 Hsp# Inhibitor 49 HCV polymerase 49 daily subcutaneous injections 49 5q chromosome 49 controlled multicenter 49 Cytarabine Liposome Injection 49 diabetes mellitus DM 49 transient insomnia 49 clinicaltrials 49 IPL# 49 TACI Ig 49 Arch Surg 49 multicenter study 49 Medullary thyroid cancer 49 PARP inhibitor 49 unfavorable prognostic 49 Canvaxin TM 49 homozygous 49 intravenous CK # 49 chromosome translocations 49 #I TM# 49 pancreatic enzyme supplements 49 rhinovirus infection 49 lysosomal enzyme iduronate 49 ribavirin therapy 49 hepatocellular carcinoma liver 49 LymphoStat B belimumab 49 Allovectin 7 ® 49 MYDICAR ® 49 nucleotide analogue 49 Denufosol 49 HNSCC 49 idiotype protein 49 tremelimumab 49 stage IIIb IV 49 TASKi2 49 fatal neuromuscular disorder 49 metastatic uveal melanoma 49 metastatic dermatofibrosarcoma protuberans DFSP 49 ANCA associated 49 Cervista HPV HR 49 apoE4 49 dietary questionnaires 49 generation purine nucleoside 49 Proellex TM 49 postherpetic neuralgia 49 juvenile idiopathic arthritis JIA 49 TREANDA 49 androgen receptor antagonist 49 systemic juvenile idiopathic 49 Pharmacokinetics PK 49 hyper IgE syndrome 49 Engerix B 49 IL# PE#QQR 49 telaprevir dosed 49 Amrubicin 49 Hedgehog Pathway Inhibitor 49 Randomized Phase 49 dyslipidaemia 49 comorbid ADHD 49 Amigal 49 multicenter Phase 49 Dr. McHutchison 49 pharmacodynamics 49 inflammatory arthritis 49 Insegia 49 GATTEX ™ 49 BRCA gene mutation 49 herpes zoster vaccine 49 micafungin 49 ConclusionThis 49 Pneumococcal pneumonia 49 pancreatic neuroendocrine tumors 49 undergoing coronary angiography 49 observational cohort study 49 stable angina 49 MECP2 gene 49 % CI #.#-#.# [003] 49 serum selenium 49 cervical vaginal 49 CALHM1 49 elacytarabine 49 nonpregnant women 49 ovarian endometrial 49 myopic CNV 49 JAK mutations 49 YONDELIS 49 BRCA1 BRCA2 49 oropharyngeal candidiasis OPC 49 HLA loci 49 kinesin spindle protein KSP 49 tuberous sclerosis complex 49 APOC3 49 SCN5A 49 trials RCTs 49 cutaneous T cell 49 sexually transmitted HPV 49 metastatic lung cancer 49 investigational therapies 49 prospectively enrolled 49 cervical dysplasia 49 4CMenB 49 dose intramuscular 49 Edge STudy 49 pemphigus vulgaris 49 hematological malignancy 49 idiotype 49 fibrotic disease 49 retrovirus XMRV 49 apolipoprotein E4 49 ankylosing spondylitis AS 49 radioimmunotherapy RIT 49 darapladib 49 LY# [003] 49 metastatic adenocarcinoma 49 recurrent acute pancreatitis 49 gemcitabine Gemzar ® 49 mixed hyperlipidemia 49 oral sapacitabine 49 idiopathic pulmonary fibrosis IPF 49 uninfected infants 49 EmbraceAC 49 abiraterone acetate 49 Zolinza 49 immune thrombocytopenic purpura ITP 49 BCIRG 49 HER2 overexpression 49 mutated BRAF gene 49 pDCs 49 Chronic ITP 49 Congenital Emphysema 49 BRCA1 mutations 49 omega interferon